Original Research Article | Published:

Genome-wide scans of three independent sets of 90 Irish multiplex schizophrenia families and follow-up of selected regions in all families provides evidence for multiple susceptibility genes

Molecular Psychiatry volume 7, pages 542559 (2002) | Download Citation

Subjects

Abstract

From our linkage study of Irish families with a high density of schizophrenia, we have previously reported evidence for susceptibility genes in regions 5q21–31, 6p24–21, 8p22–21, and 10p15–p11. In this report, we describe the cumulative results from independent genome scans of three a priori random subsets of 90 families each, and from multipoint analysis of all 270 families in ten regions. Of these ten regions, three (13q32, 18p11–q11, and 18q22–23) did not generate scores above the empirical baseline pairwise scan results, and one (6q13–26) generated a weak signal. Six other regions produced more positive pairwise and multipoint results. They showed the following maximum multipoint H-LOD (heterogeneity LOD) and NPL scores: 2p14–13: 0.89 (P = 0.06) and 2.08 (P = 0.02), 4q24–32: 1.84 (P = 0.007) and 1.67 (P = 0.03), 5q21–31: 2.88 (P= 0.0007), and 2.65 (P = 0.002), 6p25–24: 2.13 (P = 0.005) and 3.59 (P = 0.0005), 6p23: 2.42 (P = 0.001) and 3.07 (P = 0.001), 8p22–21: 1.57 (P = 0.01) and 2.56 (P = 0.005), 10p15–11: 2.04 (P = 0.005) and 1.78 (P = 0.03). The degree of ‘internal replication’ across subsets differed, with 5q, 6p, and 8p being most consistent and 2p and 10p being least consistent. On 6p, the data suggested the presence of two susceptibility genes, in 6p25–24 and 6p23–22. Very few families were positive on more than one region, and little correlation between regions was evident, suggesting substantial locus heterogeneity. The levels of statistical significance were modest, as expected from loci contributing to complex traits. However, our internal replications, when considered along with the positive results obtained in multiple other samples, suggests that most of these six regions are likely to contain genes that influence liability to schizophrenia.

Introduction

Schizophrenia is a relatively common, often chronic and debilitating mental illness. Evidence from a variety of types of studies has clearly demonstrated that genetic factors contribute substantially to the etiology.1,2 Several lines of evidence show that the mode of transmission is complex, including multiple, potentially interacting genes, along with locus heterogeneity and incomplete penetrance.2,3,4,5 As with most complex diseases, despite tremendous efforts devoted to segregation, epidemiological, family, adoption, and twin studies, little detail is known about the fundamental features of the genetic architecture. Without a good estimate of the number of important genes, plausible hypotheses about their mechanism of action, or some idea of the relative roles of epistasis and heterogeneity, debates over ‘the’ optimal set of ascertainment and analytic strategies will inevitably continue.6,7 Furthermore, many power analyses8,9,10,11 have shown that the sample sizes needed to detect susceptibility loci for complex diseases by linkage methods alone are far greater than for Mendelian disorders. Since collection of large samples is difficult and expensive, false-negative linkage results may remain a major problem. These difficulties are compounded by the heterogeneity and variability of the symptoms that comprise the clinical phenotype and by the limited flexibility and functionality of current genetics software. It is no surprise, therefore, that susceptibility genes have not yet been identified by either the positional or functional candidate approaches.

However, the availability of the complete human genomic sequence, along with technology advances and cost reductions in single nucleotide polymorphism (SNP) identification and genotyping, are compelling reasons to be cautiously optimistic. In parallel to these two major developments, incremental but important progress has been made due to the coordination of genome-wide scans with more targeted replication studies of promising regions by worldwide consortia.12,13,14,15 Many regions now have support from multiple independent studies, although due to major methodological differences between studies, the cumulative strength of the evidence for each locus remains difficult to judge. Recent reviews,16,17,18,19,20 when taken together, provide a fairly comprehensive catalog of the most positive studies, but it is likely that negative results are substantially under-represented in the literature. At the moment, the following ten regions are, arguably, those most deserving of higher density mapping and follow-up studies: 1q21–22,19,21,22,23 1q32–42,19,24,25,26,27,28 5q21–35,29,30,31,32,33 6p24–21,14,34,35,36,37,38 6q13–26,39,40 8p22–21,14,32,41,42,43,44 10p15–11,45,46,47 13q14–32,43,48,49,50,51 15q13–15,40,52,53,54 and 22q11–13.12,13,55,56,57,58,59,60,61 A second tier of regions of interest might include 2p14–13,36,46,56,59,62 2q12–13,36,46,63 4q24–32,32,40,56,63,64 9q21–22,36,64 10q11–23,46,59,63,65,66 18p11–q1167 and Xp11.64,68,69,70,71

The Irish Study of High Density Schizophrenia Families (ISHDSF) contains 1425 individuals with DNA available in 270 families systematically ascertained from psychiatric facilities in Ireland and Northern Ireland. In previous studies with these families we have, in conjunction with other research groups, generated support for the presence of four loci influencing the vulnerability to schizophrenia, on chromosomes 5q21–31,29 6p24–p21,34 8p22–21,42 and 10p15–11.45 In these previous reports, we analyzed all families together, and the 6p report did not contain multipoint results. In this report, we describe the results from additional genotyping on 5q and 6p, and of pairwise linkage analysis of three independent genome scans, performed on subsamples of 90 families each. We also report multipoint results from each subsample and from all 270 families after follow-up of ten regions of current interest.

Materials and methods

Pedigree ascertainment and diagnostic assessment

A detailed description of the Irish Study of High Density Schizophrenia Families (ISHDSF) has been published.72 The linkage sample that was used for our previously reported studies of chromosomes 5q, 6p, 8p, and 10p contained 1408 individuals from 265 systematically ascertained multiplex schizophrenia families collected in Ireland and Northern Ireland. The linkage sample that was used for the majority of the scan and for most of the follow-up analyses reported on here contained 1425 individuals from 270 families. Most of the 17 additional individuals were genotyped from the start, but their genotypes were included in the analyses only after we resolved familial inconsistencies by identity testing, and substitution of the correct DNA aliquot. Their inclusion had a negligible effect on the results.

The diagnostic instruments included the Structured Interview for DSM-III-R Diagnosis (SCID)73 and the Structured Interview for Schizotypy (SIS).74 Diagnosis was made, using DSM-IIIR criteria, based on all available information (personal history, hospital record, family history report) by individuals blind to knowledge of genotypes and to the psychopathology of relatives. The diagnostic categories are as follows. NARROW (categories D1 through D2; 625 affecteds, 565 genotyped): ‘core schizophrenic phenotypes’; schizophrenia, poor outcome schizoaffective disorder (PO-SAD) and simple schizophrenia.75 INTERMEDIATE (categories D1 through D5; 804 affecteds, 691 genotyped): a Narrow definition of the schizophrenia spectrum plus disorders which have been repeatedly shown to co-aggregate in families with narrowly defined schizophrenia.76 This category adds to the Narrow definition schizotypal personality disorder, and all other nonaffective psychotic disorders (ie schizophreniform disorder, delusional disorder, atypical psychosis and good-outcome SAD). BROAD (categories D1 through D8; 888 affecteds, 744 genotyped): a broad definition of the schizophrenia spectrum and includes all disorders which significantly aggregated in relatives of schizophrenic probands in the Roscommon Family Study,77,78,79 an epidemiologic, controlled family study conducted in parallel in the west of Ireland. This category adds to the Intermediate definition mood incongruent and mood congruent psychotic affective illness, and paranoid, avoidant and schizoid personality disorder. VERY BROAD (categories D1 through D9; 1172 affecteds, 952 genotyped). This category adds to the Broad definition all other psychiatric disorders (eg nonpsychotic affective disorders, anxiety disorders, alcoholism and other non-schizophrenia spectrum personality disorders).

Genome scan—split sample design

The most severe problem encountered during a genome scan is that of type 2 errors (ie false negatives), which will, by definition, remain undetected. Therefore we sought study design features that might reduce the impact of those variables that hinder the ability to detect linkage. Both simulations and empirical results have consistently shown that for traits in which both the phenotype and the genetic architecture are complex, the relationship between the statistical significance of the linkage results for a region and the true likelihood of a susceptibility gene being present is far from straightforward.80,81,82,83,84,85,86,87,88,89,90 To further assume that it is a direct one and rely only on the absolute values of the linkage statistics91 is unfounded and unwise. Instead, independent replication is the most useful statistical approach to distinguishing true from false positives. Prior to the start of the genome scan, we divided the 270 families at random into three subsets of 90 families each (Family sets A, B, and C). We have analyzed a number of important variables (family size distribution, number of affecteds, diagnostic classifications, geographical location, etc), and as expected, the characteristics of the three sets were similar. One notable difference is that while the number of affecteds genotyped is similar due to chance, the total number of affected sib pairs is greatest for Family set A and least for C.

Markers and maps

The markers were predominantly tri- and tetra-nucleotide repeat microsatellites generated by the Cooperative Human Linkage Center (CHLC), and many of these are in the Weber screening set, version 8.0. For the scan, we used the marker order, estimated distances to the telomeres, and sex-averaged intermarker distances92 from maps (‘Mfd98’) provided by the Marshfield Medical Research Center. For multipoint analysis of the followup regions, the maps were constructed directly from the ISHDSF genotyping data using the program CRI-MAP.93 A total of 166 markers were used; the total Mfd98 map distance was 472 cM and IHDS map distance was 396 cM. These regions were as follows:

Genotyping and error checking

The genotyping methods have been described.94,95 Mendelian inheritance was checked using the program Geno (version 1.1 from the Marshfield Center for Medical Genetics), and marker data used for multipoint analysis was further checked for double recombinants using the program CRI-MAP.93

Linkage analysis

Pairwise LOD scores (H-LODs) were calculated under the assumption of heterogeneity using the program MENDEL.96 The parameters used have been published,34 and we have kept these parameters constant for all work to date except where noted. We have made no attempts to increase the significance of the findings by using additional programs or by varying the parameters or conditions of the analysis. Pairwise H-LODs calculated using GENEHUNTER (v1.3)97 gave very similar results for a test set of 20 markers over a large range of scores (>3.0 to <−3.0, data not shown). Marker allele frequencies were calculated from all available unrelated individuals (n > 250). We used four genetic models: dominant (Dom), additive on the penetrance scale (intermediate heterozygotic; Pen), additive on the liability scale (Lia) and recessive (Rec). We present only the maximum H-LOD score for each marker. Using the program GENEHUNTER (v1.3),97 multipoint H-LODs and nonparametric linkage (NPL) scores were generated over the follow-up regions (where results are expressed in LOD and normal deviate (z) units, respectively). We report only the NPLall statistic, which is calculated based on group-wise S(all) allele sharing among affecteds in sibships. For all marker-Family Set combinations, we ran 16 (4 genetic models × 4 diagnostic categories) pairwise H-LOD calculations. In addition, for about one-third of the markers, we also ran pairwise NPL calculations, but under diagnostic categories Narrow and Broad only. The present report is both explicit and complete in terms of the number and types of tests performed. The four genetic models used are not independent and neither are the four diagnostic models, thus a correction based on 16 tests would be unduly conservative—no corrections were made.

Multiple testing

The debate over the relative utility of parametric and non-parametric tests is unresolved, so we used both. Theoretically, non-parametric analyses are inherently less powerful than parametric analyses run using a suitably correct model,98 and the LOD score will tend to maximize under the ‘correct’ model.98,99 However, not only is this model unknown, it is certainly not the same for all loci, families, and populations. The fieldwork to ascertain the families, plus the clinical diagnostic work thereafter, represents a tremendous investment of time and resources. To increase the chances of having included at least one analysis that is correct enough to generate a signal that is readily identifiable above background, we routinely ran many tests. The inflation of the type 1 error (ie false positive) rate we have incurred due to multiple testing is probably significant, but we think that this is far less detrimental than missing a true linkage. We expected the split sample design to effectively control type 1 errors, and in practice we found that the use of the two remaining subsamples for ‘internal replication’ served to rapidly identify many signals (data not shown) that were likely to be false. With three subsamples, we had the opportunity to replicate not once, but twice, before reporting our results to other groups, and we did so before preparing our four previous chromosome specific reports.

Results

Sample characteristics

Some of the characteristics of the samples that are most relevant to the linkage results are shown in Table 1. Most (88%) of the genome was scanned using individual Family Sets, but it should be noted that each set contains more families (90) and, under the Broad diagnostic category, contains more affected individuals (287–309) and more total affected sib pairs (188–242) than most of the samples used in published genome scans. Since power considerations are central, the most germane comparisons between our results and those from other studies are those that use the results from each of the three Family Sets separately, rather than simply using the results from the total sample. Eventually, all 270 families were tested in ten regions (totaling about 12% of the genome), for which the prior probability of linkage was higher.

Table 1: Selected characteristics of the samples

The actual course of the scan

We carried out three inter-digitating genome scans in parallel, testing three random subsets of families (sets A, B, and C), each initially at low resolution (>30 cM). For each Family Set, the majority of the genome was covered only at medium density, with sizable gaps, and so multipoint analysis was not possible for most of the genome. After each round of marker testing, we relied therefore on the pairwise results to prioritize further genotyping. Those regions with multiple adjacent markers that were positive (H-LOD greater than 0.5) in more than one Family Set were followed up. This was done by testing the other two subsets with the same markers, testing additional markers, and finally, for some regions, by multipoint analysis of all 270 families (ie Family Set ABC). During the course of these three genome scans, we also tested internal follow-up markers and many markers in other regions that were either positive in other studies or that contained ‘functional’ candidate genes. As a result of this mixture of scan and extensive follow-up work, marker spacing and progress on the individual scans was not systematic, and in the final analysis, inefficient. This is reflected in the uneven final map distribution of markers, the number of sizeable gaps that remain, and a number of negative regions that contain a relatively high density of markers from follow-up of external positives.

Maps and final intermarker distances

For the scan, we used the sex-averaged, 3672 cM total, ‘Mfd98’ maps92 from the Marshfield Medical Research Center. For the follow-up regions, the genotypes from the families were used to construct new maps, which were used in the multipoint analysis. A total of 684 microsatellite markers were used (mean heterozygosity 75%), 85% of which contained tri- or tetra-nucleotide repeats. Table 2 shows the numbers of markers used and the final Mfd98 map distances. Overall, there were a total of 1048 marker/Family Set combinations tested: 353 (164 unique) on Family Set A, 341 (155 unique) on Family Set B, and 354 (169 unique) on Family Set C. Including the (estimated) distances to the telomeres, the final mean intermarker distance was 9.3, 9.8, and 9.6 cM for Family Sets A, B, and C respectively. If the Family Sets are assumed to be equivalent, the final intermarker distance is 5.3 cM, with no gaps >20 cM.

Table 2: Markers and map distances

Genome-wide pairwise H-LOD results

The complete database of pairwise H-LOD and NPL results, including those generated under the Dom and Lia genetic models is entitled ‘VCU-ISHDSF-LODS’ and is available from the Virginia Institute for Psychiatric and Behavioral Genetics (VIPBG) web site. The genome-wide, maximum pairwise H-LODs are plotted for two of the four diagnostic categories in Figures 1 (Narrow) and 2 (Broad). For clarity, only the results under the Pen (filled diamonds) and Rec (open diamonds) genetic models are shown, since results Dom are usually similar to Pen, and results under Lia are similar to Rec. The vast majority of markers must be unlinked, but each will still produce a maximum H-LOD near or at zero at large recombination fractions. Overall, about 12% of all combinations of markers and Family Sets tested gave H-LODs greater than 0.5, regardless of the combinations of Diagnostic Category and Genetic Model used. Figures 1 and 2 show that the baseline of H-LOD scores is in the range of 0.0–0.5, which is the empirical baseline we used to define the linkage signals.

Figure 1
Figure 1

The program MENDEL96 was used to calculate pairwise LOD scores under the assumption of locus heterogeneity (H-LODs). The maximum score, attained at any recombination fraction and proportion linked, is plotted at the marker location. Results from three independent subsets of 90 families each (Family Sets A, B, and C) and the entire 270 families (Family Set ABC) are shown. For each Family Set, calculations were performed under four hierarchical diagnostic categories: Narrow (D1–D2, Figure 1), Intermediate (D1–D5, not shown), Broad (D1–D8, Figure 2), and Very Broad (D1–D9, not shown), and four genetic models: Dom (not shown), Pen (penetrance, filled diamonds), Lia (not shown), and Rec (recessive, open diamonds). Marker locations are as described in the legend to Table 2.

Figure 2
Figure 2

The program MENDEL96 was used to calculate pairwise LOD scores under the assumption of locus heterogeneity (H-LODs). The maximum score, attained at any recombination fraction and proportion linked, is plotted at the marker location. Results from three independent subsets of 90 families each (Family Sets A, B, and C) and the entire 270 families (Family Set ABC) are shown. For each Family Set, calculations were performed under four hierarchical diagnostic categories: Narrow (D1–D2, Figure 1), Intermediate (D1–D5, not shown), Broad (D1–D8, Figure 2), and Very Broad (D1–D9, not shown), and four genetic models: Dom (not shown), Pen (penetrance, filled diamonds), Lia (not shown), and Rec (recessive, open diamonds). Marker locations are as described in the legend to Table 2.

Pairwise results: effect of the genetic model

There did not seem to be any obvious, systematic effect of the genetic model (here Pen vs Rec) on the H-LODs, either for markers across the genome as a whole, or in the ten follow-up regions.

Pairwise results: effect of the diagnostic category

Some markers tested on Family Set ABC in some follow-up regions showed a marked dependence on the diagnostic category used. This can be seen in the pairwise results presented in Figures 1 and 2 and also in the multipoint results summarized in Table 4 and shown in more detail in Figures 3456. For example, on 5q under the Rec model, the Narrow category produces by far the greatest multipoint H-LOD scores (see Figure 5b), while on 6p (Figure 6b), the Intermediate and Broad categories are both greater than either Narrow or Very Broad. On 10p (not shown), the Intermediate category is stronger than the other categories. Chromosomes 2p and 4q are less positive in general, and show few differences across diagnostic categories.

Table 4: Maximum multipoint H-LOD and NPL scores from different Family Sets
Figure 3
Figure 3

Multipoint H-LOD and NPL results from all 270 families in four of the ten follow-up regions: 2p14–13 (Figure 3), 4q24–32 (Figure 4), 5q21–31 (Figure 5), and 6p24–21 (Figure 6). For each region, based on the pairwise results, we chose the diagnostic category which in general yielded the highest H-LODs and varied the genetic models (shown in Panel a). Likewise, we chose the ‘best’ genetic model and varied diagnostic category (shown in Panel b). Panel (c) shows the NPL results for the four diagnostic categories. Calculations were done using the program GENEHUNTER (v 1.0).97 Maps were constructed from the ISHDSF genotypes using the program CRI-MAP,93 which was also used for error checking.

Figure 4
Figure 4

Multipoint H-LOD and NPL results from all 270 families in four of the ten follow-up regions: 2p14–13 (Figure 3), 4q24–32 (Figure 4), 5q21–31 (Figure 5), and 6p24–21 (Figure 6). For each region, based on the pairwise results, we chose the diagnostic category which in general yielded the highest H-LODs and varied the genetic models (shown in Panel a). Likewise, we chose the ‘best’ genetic model and varied diagnostic category (shown in Panel b). Panel (c) shows the NPL results for the four diagnostic categories. Calculations were done using the program GENEHUNTER (v 1.0).97 Maps were constructed from the ISHDSF genotypes using the program CRI-MAP,93 which was also used for error checking.

Figure 5
Figure 5

Multipoint H-LOD and NPL results from all 270 families in four of the ten follow-up regions: 2p14–13 (Figure 3), 4q24–32 (Figure 4), 5q21–31 (Figure 5), and 6p24–21 (Figure 6). For each region, based on the pairwise results, we chose the diagnostic category which in general yielded the highest H-LODs and varied the genetic models (shown in Panel a). Likewise, we chose the ‘best’ genetic model and varied diagnostic category (shown in Panel b). Panel (c) shows the NPL results for the four diagnostic categories. Calculations were done using the program GENEHUNTER (v 1.0).97 Maps were constructed from the ISHDSF genotypes using the program CRI-MAP,93 which was also used for error checking.

Figure 6
Figure 6

Multipoint H-LOD and NPL results from all 270 families in four of the ten follow-up regions: 2p14–13 (Figure 3), 4q24–32 (Figure 4), 5q21–31 (Figure 5), and 6p24–21 (Figure 6). For each region, based on the pairwise results, we chose the diagnostic category which in general yielded the highest H-LODs and varied the genetic models (shown in Panel a). Likewise, we chose the ‘best’ genetic model and varied diagnostic category (shown in Panel b). Panel (c) shows the NPL results for the four diagnostic categories. Calculations were done using the program GENEHUNTER (v 1.0).97 Maps were constructed from the ISHDSF genotypes using the program CRI-MAP,93 which was also used for error checking.

Our prior Irish family study100 had suggested that the susceptibility genes for schizophrenia were perhaps largely distinct from those conferring risk to other non-schizophrenia spectrum psychiatric syndromes such as alcoholism or anxiety disorders. Therefore it was surprising that, for many markers, the scores under the Very Broad category were either comparable to, or greater than, those obtained under the Broad category. For example, three 8p markers tested on Family Set ABC gave the following results for Broad and Very Broad categories respectively: D8S1731 (0.17 and 2.40), D8S1715 (0.20 and 2.01), and D8S133 (0.46 and 1.79). Likewise, both H-LOD and NPL multipoint analysis of 8p gave similar results for the Broad and Very Broad diagnostic categories (not shown). Similar results (see also Table 3) were obtained with Family Set B and pairwise analysis of 6p markers D6S259, D6S285, D6S291, and 8p markers D8S1731 and D8S1752.

Table 3: Markers with pairwise H-LOD scores greater than 2.0 on one or more Family Sets

Pairwise results: effect of testing different Family Sets

Even though families were randomly assigned, for a given region the magnitude of the scores varied substantially across the three Family Sets. The most striking asymmetry is on 10p, where under the Intermediate category, Family Set A has two markers that produce H-LODs >3.0, and a number of others between 1.5 and 3.0 (data not shown). Family Set B is much weaker, and Family Set C produces no scores above baseline. Family Set A is stronger under the other three diagnostic categories also (eg Broad in Figure 2). The multipoint H-LOD maxima for each of the three Family Sets were in almost the exact locations, but the values were very different: 2.86, 0.87 and 0.0 respectively (see Table 4 below). Similar results were found with multipoint NPL scores.

In contrast to 10p, where Family Set A was by far the most positive, for a number of markers on 2p, the pairwise results from Family Set C were greatest, especially under the Very Broad category. This was also observed in the multipoint H-LOD scores (0.13, 0.07, and 1.20 for Family Sets A, B, and C respectively) and the NPL scores (0.61, 0.75, and 2.93 respectively).

Pairwise results: regions with primarily negative scores

The most noteworthy of the negative regions are 13q (see Table 4), and 22q, both of which have gathered substantial support in multiple studies. On chromosome 22, the maximum result score with marker D22S278 on all families was 0.51, and the vast majority of scores from individual Family Sets were less than 0.5. Since multiple flanking markers were also negative (data not shown), we did not pursue this region further. The same was true of the majority of the markers in region 1q21–q32. Some of the markers on 6q did appear to be above the baseline of pairwise results, but the maximum multipoint H-LOD was only 0.71.

Pairwise results: markers with the greatest H-LODs

We identified those markers that, under any of the analyses, yielded pairwise H-LODs >2.0 on at least one Family Set. All 28 such markers are shown in Table 3, arranged in chromosomal order. The largest score observed in the scan and follow-up was 3.88, from D2S428 on Family Set C. This 2p result is noteworthy, but unfortunately Family Set C produces virtually all of the positive results. While the three best 4q results were with Family Set A, additional evidence comes from B. Overall, the two strongest clusters of pairwise H-LODs were on 6p and 10p—each cluster had two markers with scores >3.0. On 10p, eight markers in the interval including D10S1412 and D10S1220, were positive under the Intermediate category, and across all genetic models, all on Family Set A. On 6p, D6S259, D6S285, and D6S291 were most positive, under the Very Broad diagnostic category. Note that D6S291 is actually distal to HLA and is over 15 cM proximal to the 6p23 multipoint peak (see Figure 6). As mentioned, the fact that the broadest diagnostic category would produce the greatest overall number of large pairwise H-LODs was quite unexpected.

Locations of the ten follow-up regions

We,101 and others102,103 well before us, have shown that with small samples, the location of maximal evidence from a gene of small effect size can vary considerably. For each region, therefore, we chose markers that included those regions containing the maximal evidence in the most convincing of the previous reports. The number of markers tested on all 270 families, the locations of the markers that bound the regions, and the length of each region are all given in the Methods section. The combined length according to the Mfd98 map is 473 cM, or about 12% of the genome. When calculated from genotypes of the family members, the length is 397 cM (84%). This could be due to a lower error rate in the genotypes we used to make our map, and/or to the considerably higher Mfd98 map density.

Multipoint analysis of ten regions: results from all families

During the course of the genome scan and follow-up work, we tested markers as dictated by our own independent scan results (6p, 5q, 10p) as well as by the findings of other studies of schizophrenia (2p, 4q, 5q, 6q, 8p, 13q, 18pq and many others) and bipolar disorder (13q and 18q). The markers on 8p and 10p used in the multipoint analysis presented here are identical to those used in our two previous publications.42,45 The number of markers presented here is greater on both 5q (35 here vs 14) and 6p (34 vs 11) than used previously.29,34 In addition, our report on 6p lacked multipoint results, and none of the four previous reports showed results from individual Family sets.

For each region, based on inspection of the patterns of the pairwise scores, we chose the ‘best’ combination of genetic model and diagnostic category, ie the one we thought most likely to produce the greatest multipoint scores. For some regions (eg 5q) the choice was clear, but for most it was not. In order to convey the substantial variability in the strength of the evidence, as well as its complexity, we present three graphs for each region. Figures 36 each contain three panels: (a) H-LODs calculated under the best diagnostic category, and all four genetic models; and H-LODs (b) and NPL scores (c), each calculated under different diagnostic categories. These multipoint curves are usually quite complex and highly dependent on the diagnostic category. In some cases there are multiple peaks of similar magnitude, located at very different locations (eg 2p, Figure 3), and in other cases the evidence is relatively constant across very large genomic regions (eg 4q, Figure 4). In contrast, some results are reasonably simple, and thus more useful for fine mapping—for example the H-LOD peaks on 5q (Figure 5), 6p (Figure 6), and 10p (not shown) are both more distinct and more consistent with the pairwise results than those from most other regions. When 34 markers were analyzed, 6p showed two distinct peaks, a distal peak near D6S470 (6p25–24) and a proximal peak in the region between D6S260 and D6S1676 (6p23). Interestingly, at the 24 marker stage, these two peaks were not well defined.

Multipoint analysis of ten regions: results from family sets

To provide a more convenient summary of the many multipoint results from Family Set ABC shown in Figures 36, as well as for six other regions for which the multipoint graphs are not shown, in Table 4 we show the maximum H-LOD and NPL scores and their locations for each region. Results from the individual Family Sets are also included. The curves are usually complex, and a great deal of contextual information is lost when only a small amount is extracted. For example, Family Set B produced positive scores throughout much of the region (ie the peaks are not well defined), whereas Family sets A and C resemble the results shown in Figure 6.

The multipoint results are in general agreement with the pairwise results. Regions 5q, 6p, and 8p produce the most consistent scores across Family Sets, and the largest scores on Family Set ABC. On 10p, Family Set A is by far the strongest, producing a maximum multipoint H-LOD of 2.86 and maximum NPL of 3.24. Conversely, on 2p, Family set C produces an H-LOD of 1.20 and an NPL of 2.93. There appears to be some degree of support for regions 4q, 6q, and 18q. However, inspection of the pairwise scores contained in the full database shows that across a number of additional markers tested only on individual family sets, global support for 18q is actually fairly weak. D18S554 is 7 cM from the telomere, and virtually all of the pairwise evidence from Family Sets A and C is from that marker alone. There is no support for regions 13q and 18pq.

Multipoint results from individual families in the ten follow-up regions

From the analyses that produced the results shown in Table 4, we recorded the maximum scores achieved by each individual family, anywhere in each of the ten regions. In Table 5, we show the distribution of these maximum values, for each region individually. Below these results, for regions 5q, 6p, 8p, and 10p we show the numbers of families that are positive on combinations of two, three or all four chromosomes.

Table 5: Distribution of individual family (n = 270) maximum multipoint H-LOD and NPL scores from the follow-up regions

We have calculated the proportion of linked families, but given the potential problems associated with this estimation,104 we can only tentatively posit a wide range of 5–30% for each of these four regions. We might expect, therefore, between 13 and 81 families to be linked to any one region. The (cumulative) cut-offs shown in Table 5 were chosen to reflect this estimate, even though with small families, linkage scores are inaccurate predictors of the presence of risk allele(s). Nevertheless, 13–81 families corresponds roughly to H-LODs of >0.5 to >0.7, and to NPL scores of >1.4 to >2.4. We found that a total of only 74 families had NPL scores greater than 2.0 on any of the ten regions (data not shown). Very few of the 270 families show large H-LOD or NPL scores on more than one region. Only one family (01226) shows NPL scores greater than 3.0 on all four of the regions reported previously.

In Table 6, we show data from the 12 families that gave scores >2.0 on three or more of the ten regions. An additional 11 families showed scores >2.0 on two or more regions (data not shown). Note that family 1226 yields NPL scores >3.0 on five of the ten regions, and is positive on two more (18q, NPL = 2.63 and 4q, NPL = 1.63) as well. Also shown in Table 6 are the rank of each of the NPL scores from family 01226 relative to all 270 families. It is extraordinary that the six best NPL scores produced are all within the top 1.5% (four of 270) produced in the entire study for those six regions. Family 01226 contains a sibship with four affected brothers, but is otherwise unremarkable—a number of other families are similar in structure.

Table 6: Individual family multipoint NPL scores in the follow-up regions

Discussion

Effect of varying the genetic model

For all six regions that appear most promising in our sample, scores under the genetic models Dom and Pen are strongly correlated, as are those under Lia and Rec. Consistent with the work of Greenberg et al,98,99 we would have obtained nearly the same results with the use of two rather than four genetic models. For most positive regions, Pen and Rec are about equal in generating the best pairwise results. In contrast, the multipoint results are generally stronger under Dom or Pen models, with the exception of region 10p, where Rec and Lia models are somewhat better. No strong inferences can yet be made regarding the likely mode of action of any of these putative loci. These findings are consistent, though, with the assumption that different susceptibility loci can have different biological effects.

Effect of varying the diagnostic category

We used four diagnostic categories to minimize type 2 errors, and to try to gain insight into the nature of the risk conferred by individual loci. If for a given region a particular diagnostic category consistently produced much larger linkage signals, it may mean that the liability towards particular clinical symptoms is due to at least in part to variation at that locus. The magnitude of the H-LODs varied more, and varied on more regions, with changes in the diagnostic category than with changes in the genetic model. The region showing the greatest dependence on diagnostic category is 5q, where the Narrow category produced by far the highest H-LODs and NPL scores. On 6p, the Intermediate and Broad categories produced similar and stronger signals than either the Narrow or Very Broad categories. Region 8p is the one where the Very Broad category is the most positive. On 10p, the Intermediate category yielded better scores on average. One plausible interpretation of these results is that the ‘spectrum of action’ of individual susceptibility loci differs. That is, perhaps some of the ‘schizophrenia’ loci that we are observing may predispose individuals only to the narrowly defined psychotic illness of schizophrenia (eg 4q, 5q), while others may also increase risk to a broad range of schizophrenia spectrum disorders (6p23, 6p25–24, 10p), and others (8p) may influence vulnerability to an even wider range of psychiatric conditions, including anxiety and affective disorders.

Replication of linkage

The degree to which negative reports should detract from positive evidence for linkage in complex traits is controversial. Simulation studies predict that ‘non-replications’ of true linkages will be common when small, heterogeneous samples are used to detect genes of small effect.8 Furthermore, to date, because of cross-study heterogeneity of sample sizes, populations studied, ascertainment strategies, diagnostic methods, and statistical techniques,105 all follow-up studies in schizophrenia are not truly ‘replication’ attempts in any strict sense. When follow-up results differ from the original ones, usually no firm conclusions as to the cause can be drawn. Replication in comparable independent samples is critical. We randomly assigned the families to the three Family Sets after ascertainment and diagnosis was completed, and before the systematic scan started. Each set had greater power to detect linkage than most other schizophrenia linkage samples. Therefore, by design, we had a good opportunity to perform a more valid and interpretable ‘replication study’ than had been achieved previously.

Distribution of positive evidence across the three Family Sets

Two of the six positive regions we examined carefully (2p and 10p) failed to ‘replicate’ in either of the two other subsamples. This may indicate that these findings are false positives. Alternatively, it is possible that these regions do contain susceptibility genes and that non-replication of true linkages may actually be much more prevalent than commonly thought. There was much less asymmetry in the distribution of positive evidence in regions 5q, 6p, and 8p, where the evidence for second best sample was usually similar to the best. Given our current state of ignorance about the stochastic properties of linkage in complex diseases, we can at most conclude from this study that the more consistently replicated regions are more likely to contain true susceptibility genes than are regions where positive evidence for linkage cannot be replicated.

Comparison with findings from other studies

A detailed evaluation of what has become a tremendous number of positive linkage findings in schizophrenia is not possible here. In brief, we found no evidence to support the putative schizophrenia loci in regions 13q32 or 18p11–q11, or the bipolar disorder locus in 18q22–23.106 Pairwise results were negative for regions 3p25–24,41 5p14–p13,107 and 5q11–13,108,109 and 15q.52,54 We have already published our primary positive evidence for regions 5q21–31, 6p24–21, 8p22–21, and 10p15–11. In this report, we provided additional detail on all four of these regions, including the evidence from each of the three Family Sets, and showed that for 10p, Sets B and C failed to corroborate the very strong findings from Set A. We also showed additional marker data on 6p24–21 that suggests the possibility of two genes—one in 6p25–24 and one in 6p23. Two additional regions also produced evidence in support of linkage, 2p14–13, and 4q24–32, and we noted that 2p failed to produce consistently positive scores on two of the three Family Sets. Region 6q13–2639,40 yielded only small positive scores, but the pattern is interesting and the region deserves further study.

The following seven candidate regions have not yet been subjected to a thorough investigation, (ie multipoint analysis of all families): 1q32.2–42,64,110 2q12–13,36,46,63 9q21–22,36,40,63 10q11.2–23,46,59,63,65 15q14,40,52,53 22q12–13,12,13,55,56,57,58,59,60,61 and Xp11.4–11.3.64,68,69,70,71 While they are positive in some other studies, the pattern of our pairwise scores was sufficiently negative that we did not pursue them further. We have tested many markers in these regions (on either one or two Family Sets), in addition to those used for the multipoint analysis shown here, and there is important information contained in the pairwise results that are not shown. Since in scan data consideration of the context of the score from any individual marker is crucial, it is necessary to consider all of the data together when evaluating the overall support for these, and other, candidate regions. To this end, we have made all of the pairwise results available from the VIPBG web site.

Conclusions

In light of the relatively weak linkage statistics obtained, and the complexity of the results across the independent family sets and across analyses, only a few tentative, quite general conclusions are supported. First, three regions (13q, 18pq and 18q) clearly differ from the others in not having consistently generated pairwise scores greater than those typical of the scan baseline. Of the remaining seven regions, 2p and 6q show the weakest pairwise H-LOD scores and the least consistent multipoint peaks, although the NPL multipoint results look somewhat more promising. Regions 4q, 5q, 6p, 8p, and 10p all produce evidence of the sort that now appears to be characteristic of genes of moderate effect size in complex traits. Even in the absence of highly ‘significant’ results, overall the strength of the data for these regions is sufficient to justify high density mapping to detect linkage disequilibrium (LD). We have pursued such a strategy on 6p and have recently generated evidence of LD very close to each of the two multipoint peaks (manuscript in preparation). Second, the pattern of internal replication differed substantially between these positive regions. While the meaning of these differences is unclear, were we restricted to our own data, we would have to conclude that the regions with clearer internal replications (5q, 6p, 8p) are more likely to be true findings than are the regions that replicate poorly, especially 2p and 10p. However, the evidence from other groups in support of the 10p locus is now quite strong. Third, it appears from the scores from individual families in the candidate regions, that locus heterogeneity, as opposed to a simple additive model for example, is likely to be a predominant feature of this Irish high-density schizophrenia sample, and perhaps of familial schizophrenia overall.

Thus far we have applied only the most basic of analytic approaches on the scan data. We have not attempted to maximize the statistical significance by varying the parameters used or by applying additional tests. We have just begun more exploratory types of analyses—for example our first attempt at detecting epistatic interactions between the loci in the six most positive regions was negative,111 but more work is warranted. Approaches that are more synthetic and powerful, for example haplotype analysis that incorporates multivariate and quantitative approaches, and that allows for epistatic interactions, may serve to produce more definitive results. It is anticipated also that the application of newer methods, eg neural networks112 or classification and regression trees113 and related algorithms, when applied to data from much larger samples probed with many more markers will also be productive. Even if such analytic advances are made, however, the use of intermediate phenotypes114 as well as a battery of assays of gene function (eg differential expression115) will be required to elucidate the genetic component of schizophrenia.

Acknowledgments

This project was largely supported by grants MH41953, MH52537, and MH45390 from the United States National Institute of Mental Health (NIMH). Data collection was conducted under the supervision of S Humphries, M Healy, and A Finnerty. Additional interviews were conducted by J Burke, B Murphy, F Duke, R Shinkwin, M Ni Nuallain, F McMahon, J Downing, T Hebron, B Hanratty, E Crowe, M Doherty, J Bray, and L Lowry. This project would not have been possible without the cooperation of the families themselves and the staffs of the many psychiatric hospitals and units in Ireland and Northern Ireland and their efforts are gratefully acknowledged. We also wish to acknowledge the assistance of R McClelland.

Electronic-database information

URLs for data in this article are as follows:

  1. Cooperative Human Linkage Center (CHLC); http://www.chlc.org/

  2. Marshfield Medical Research Center: http://www. marshmed.org/genetics/

  3. The complete database, entitled VCU-ISHDSF-LODS, contains pairwise H-LODs for all markers and pairwise NPL scores for selected markers and will be available upon publication from VIPBG (Virginia Institute for Psychiatric and Behavioral Genetics) web site: (http://electro.psi.vcu.edu/vipbg/vipbghome.html).

References

  1. 1.

    , . Schizophrenia: The Epigenetic Puzzle Cambridge University Press: New York 1982

  2. 2.

    . The genetics of schizophrenia. In: Kaplan HI and Sadock BJ (eds). Comprehensive Textbook of Psychiatry Williams & Wilkins: New York 1999

  3. 3.

    , , , , . Refutation of the general single-locus model for the etiology of schizophrenia Am J Hum Genet 1982 34: 630–649

  4. 4.

    , . Genetically mediated vulnerability to schizophrenia [Review] Psych Clin North Am 1993 16: 245–267

  5. 5.

    . Turning point in the design of linkage studies of schizophrenia Am J Med Genet 1994 54: 83–92

  6. 6.

    , , . Optimal ascertainment strategies to detect linkage to common disease alleles Am J Hum Genet 1998 63: 880–888

  7. 7.

    . On the resolution and feasibility of genome scanning approaches. In: Rao DC, Province MA (eds) Genetic Dissection of Complex Traits Academic Press: New York 2001 351–389

  8. 8.

    , , . Problems of replicating linkage claims in psychiatry. In: Gershon ES, Cloninger CR (eds) Genetic Approaches to Mental Disorders American Psychiatric Press: Washington, DC 1994 23–46

  9. 9.

    , . Power of the linkage test for a heterogeneous disorder due to two independent inherited causes: a simulation study Genet Epidemiol 1990 7: 219–230

  10. 10.

    , , . Linkage studies of schizophrenia: a simulation study of statistical power Genet Epidemiol 1992 9: 123–139

  11. 11.

    . Power to detect linkage with heterogeneity in samples of small nuclear families Am J Med Genet 1993 48: 94–102

  12. 12.

    , , , , , et al. A combined analysis of D22S278 marker alleles in affected sib-pairs: support for a susceptibility locus for schizophrenia at chromosome 22q12 Am J Med Genet 1996 67: 40–45

  13. 13.

    , , , , , et al. A transmission disequilibrium and linkage analysis of D22S278 marker alleles in 574 families: further support for a susceptibility locus for schizophrenia at 22q12 Schiz Res 1998 32: 115–121

  14. 14.

    Schizophrenia Linkage Collaborative Group for Chromosomes 3 and 6 and 8—coordinated by DF Levinson. Additional support for schizophrenia linkage on chromosomes 6 and 8: A multicenter study Am J Med Genet 1996 67: 580–594

  15. 15.

    , , , , , et al. Multicenter linkage study of schizophrenia candidate regions on chromosomes 5q, 6q, 10p, and 13q: schizophrenia linkage collaborative group III Am J Hum Genet 2000 67: 652–663

  16. 16.

    , . Dissecting the genetic complexity of schizophrenia Mol Psychiatry 1997 2: 211–223

  17. 17.

    , . Linkage and associated studies of schizophrenia Am J Med Genet 2000 97: 23–44

  18. 18.

    . Genetics of schizophrenia and the the new millennium: progress and pitfalls Am J Hum Genet 2001 68: 299–312

  19. 19.

    , , , , , et al. Genome wide linkage analysis supports the presence of two separate susceptibility loci on chromosome 1q32 for biopolar disorder and 1q21–22.3 for schizophrenia [Abstract] Am J Med Genet 2000 96: 400

  20. 20.

    , . Searching for schizophrenia genes Trends Mol Med 2001 7: 169–174

  21. 21.

    , , , , , et al. A genomewide screen for schizophrenia genes in an isolated Finnish subpopulation, suggesting multiple susceptibility loci Am J Hum Genet 1999 65: 1114–1124

  22. 22.

    , , , , . Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21–q22 Science 2000 288: 678–682

  23. 23.

    , , , , , et al. Fine-mapping of a 40 CM region on chromosome 1Q in schizophrenia [Abstract] Am J Med Genet 2000 96: 461

  24. 24.

    , , , , , et al. H(2)(15)O PET validation of steady-state arterial spin tagging cerebral blood flow measurements in humans Magn Reson Med 2000 44: 450–456

  25. 25.

    , , , , , et al. Genome-wide scan for schizophrenia in the Finnish population: evidence for a locus on chromosome 7q22 Hum Mol Genet 2000 9: 1049–1057

  26. 26.

    , , , , , et al. Chromosome 1 loci in Finnish schizophrenia families Hum Mol Genet 2001 10: 1611–1617

  27. 27.

    , , , , , et al. Association within a family of a balanced autosomal translocation with major mental illness Lancet 1990 336: 13–16

  28. 28.

    , , , , , et al. Genomic structure and localisation within a linkage hotspot of Disrupted In Schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia Mol Psychiatry 2001 6: 173–178

  29. 29.

    , , , , . Support for a possible schizophrenia vulnerability locus in region 5q21–31 in Irish families Mol Psychiatry 1997 2: 148–155

  30. 30.

    , , , , , et al. Evidence suggestive of a locus on chromosome 5q31 contributing to susceptibility for schizophrenia in German and Israeli families by multipoint affected sib-pair linkage analysis Mol Psychiatry 1997 2: 156–160

  31. 31.

    , , , , , et al. Evidence for a 5q31 schizophrenia locus in a large multiplex kindred from Palau, Micronesia [Abstract] Mol Psychiatry 1999 4 (Suppl 1): S4–S5

  32. 32.

    , , , , , et al. Initial genome wide parametric genetic linkage analysis of schizophrenia and schizophrenia spectrum disorders finds LOD scores above 3.00 on four chromosomes at 1q22–23, 5q22–35, 8p21–23 and 11q14–24. A further LOD above 3.00 at 4q21–31 was found within a single family [Abstract] Mol Psychiatry 1999 4 (Suppl 1): S4

  33. 33.

    , , , , , et al. Linkage analysis for schizophrenia susceptibility loci in candidate regions on chromosomes 5q, 6q, 10q, and 13q: a collaborative follow-up effort in one sample [Abstract] Mol Psychiatry 1999 4 (Suppl 1): S32

  34. 34.

    , , , , , et al. A potential vulnerability locus for schizophrenia on chromosome 6p24–22: evidence for genetic heterogeneity Nature Genet 1995 11: 287–293

  35. 35.

    , , , , , et al. Evaluation of a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib-pair linkage analysis Nature Genet 1995 11: 325–327

  36. 36.

    , , , , , et al. An international two-stage genome-wide search for schizophrenia susceptibility genes Nature Genet 1995 11: 321–324

  37. 37.

    , , , , , et al. 6p24–22 region and major psychoses in the eastern Quebec population Am J Med Genet 1997 74: 311–318

  38. 38.

    , , , , , et al. Linkage analysis of a large Swedish kindred provides further support for susceptibility locus for schizophrenia on chromosome 6p23 Am J Med Genet (Neuropsych Genet) 1999 88: 369–371

  39. 39.

    , , , , , et al. Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees Genomics 1997 43: 1–8

  40. 40.

    , , , , , et al. NIMH Genetics Initiative Millennium Schizophrenia Consortium: Linkage analysis of African–American pedigrees Am J Med Genet 1998 81: 282–289

  41. 41.

    , , , , , et al. Schizophrenia: a genome scan targets chromosomes 3p and 8p as potential sites of susceptibility genes Am J Med Genet 1995 60: 252–260

  42. 42.

    , , , , , et al. Evidence for a schizophrenia vulnerability locus on chromosome 8p in the Irish study of high-density schizophrenia families Am J Psychiatry 1996 153: 1534–1540

  43. 43.

    , , , , , et al. Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21 Nature Genet 1998 20: 70–73

  44. 44.

    , , , , , et al. Linkage and allelic association studies of the 8p schizophrenia locus [Abstract] Mol Psychiatry 1999 4 (Suppl 1): S31

  45. 45.

    , , , , , et al. A schizophrenia locus may be located in region 10p15–p11 Am J Med Genet 1998 81: 296–301

  46. 46.

    , , , , , et al. Genome scan of European-American schizophrenia pedigrees: results of the NIMH genetics initiative and millennium consortium Am J Med Genet 1998 81: 290–295

  47. 47.

    , , , , , et al. Further evidence for a susceptibility locus on chromosome 10p14–p11 in 72 families with schizophrenia by nonparametric linkage analysis Am J Med Genet 1998 81: 302–307

  48. 48.

    . , Curtis D, Williams N, Arranz M, Nanko S, Collier D et al. Suggestive evidence for linkage of schizophrenia to markers on chromosome 13q14.1–q32 [Abstract] Psychiatr Genet 1995 5: 117–126

  49. 49.

    , , , , , . Suggestive evidence for linkage of schizophrenia to markers on chromosome 13 in Caucasian but not Oriental populations Hum Genet 1997 99: 417–420

  50. 50.

    , , , , , et al. Genetic linkage analysis in Icelandic/British family sample fails to exclude the putative chromosome 13q14.1–q32 schizophrenia susceptibility locus [Abstract] Am J Hum Genet 1996 59: A388

  51. 51.

    , , , , , et al. Linkage of familial schizophrenia to chromosome 13q32 Am J Hum Gen 1999 65: 1096–1103

  52. 52.

    , , , , , et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus Proc Natl Acad Sci USA 1997 94: 587–592

  53. 53.

    , , , , , et al. Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH Genetics Initiative Am J Med Genet 1998 81: 308–312

  54. 54.

    , , , , , et al. Linkage disequilibrium for schizophrenia at the chromosome 15q13–14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7) Am J Med Genet 2001 105: 20–22

  55. 55.

    , , , , , et al. Analysis of chromosome 22 markers in nine schizophrenia pedigrees Am J Med Genet 1994 54: 72–79

  56. 56.

    , , , , , et al. Genomic scan for genes predisposing to schizophrenia Am J Med Genet 1994 54: 59–71

  57. 57.

    , , , , , et al. Sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12–q13.1: Part 1 Am J Med Genet 1994 54: 36–43

  58. 58.

    , , , , , et al. Linkage studies on chromosome 22 in familial schizophrenia Am J Med Genet 1995 60: 139–146

  59. 59.

    , , , , , et al. A genome-wide search for schizophrenia susceptibility genes Am J Med Genet 1998 81: 364–376

  60. 60.

    , , , , , et al. Haplotypic transmission disequilibrium analysis: application to a potential locus for schizophrenia at chromosome 22q11 [Abstract] Mol Psychiatry 1999 4 (Suppl. 1): S37–S38

  61. 61.

    , , , , . Weak evidence for a susceptibility locus on chromosome 22q12 in Taiwanese schizophrenic pedigrees [Abstract] Mol Psychiatry 1999 4 (Suppl. 1): S38

  62. 62.

    , , , , , et al. Evidence for a chromosome 2p13–14 schizophrenia susceptibility locus in families from Palau, Micronesia Mol Psychiatry 1998 3: 521–527

  63. 63.

    , , , , , et al. Am J Psychiatry 1998 155: 741–750

  64. 64.

    , , , , , et al. Genomewide scan for familial combined hyperlipidemia genes in Finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels Am J Hum Genet 1999 64: 1453–1463

  65. 65.

    , , , , , et al. Genome scan of schizophrenia: results of genotyping of positive regions [Abstract] Mol Psychiatry 1999 4 (Suppl. 1): S37

  66. 66.

    , , , , , et al. Second stage of a genome scan of schizophrenia: study of five positive regions in an expanded sample Am J Med Genet 2000 96: 864–869

  67. 67.

    , , , , , et al. Support for a chromosome 18p locus conferring susceptibility to functional psychoses in families with schizophrenia, by association and linkage analysis Am J Hum Genet 1998 63: 1139–1152

  68. 68.

    , , , , , et al. Search for linkage to schizophrenia on the X and Y chromosomes Am J Med Genet 1994 54: 113–121

  69. 69.

    , , , , , et al. Linkage study of schizophrenia to markers within Xp11 near the MAOB gene Psychiatry Res 1997 70: 131–143

  70. 70.

    . X-Chromosome workshop Psych Genet 1998 8: 121–126

  71. 71.

    , . Linkage disequilibrium mapping of chromosome Xp11 for a schizophrenia susceptibility locus [Abstract] Mol Psychiatry 1999 4: 416–417

  72. 72.

    , , , , , et al. Irish study of high-density schizophrenia families: field methods and power to detect linkage Am J Med Genet 1996 67: 179–190

  73. 73.

    , , , . The structured clinical interview for DSM-III-R (SCID): I: History, rationale, and description Arch Gen Psychiatry 1992 49: 624–629

  74. 74.

    , , . The Structured Interview for Schizotypy (SIS): a preliminary report Schizophr Bull 1989 15: 559–571

  75. 75.

    , , , . An epidemiologic, clinical, and family study of simple schizophrenia in County Roscommon, Ireland Am J Psychiatry 1994 151: 27–34

  76. 76.

    , . The genetics of schizophrenia: a current, genetic-epidemiologic perspective Schizophr Bull 1993 19: 261–285

  77. 77.

    , , , , , . The Roscommon family study: I. Methods, diagnosis of probands, and risk of schizophrenia in relatives Arch Gen Psychiatry 1993 50: 527–540

  78. 78.

    , , , , , . The Roscommon Family Study: II. The risk of nonschizophrenic nonaffective psychoses in relatives Arch Gen Psychiatry 1993 50: 645–652

  79. 79.

    , , , , , . The Roscommon family study: III. Schizophrenia-related personality disorders in relatives Arch Gen Psychiatry 1993 50: 781–788

  80. 80.

    , , , , , et al. No evidence for allelic association between schizophrenia and a polymorphism determining high or low catechol O-methyltransferase activity Am J Psychiatry 1996 153: 268–270

  81. 81.

    . Effect of genetic architecture on the power of human linkage studies to resolve the contribution of quantitative trait loci Heredity (Edinburgh) 1994 72: 175–192

  82. 82.

    . Pragmatics and statistics in psychiatric genetics Am J Med Genet 1997 74: 220–222

  83. 83.

    . Significance levels in complex inheritance Am J Hum Gen 1998 62: 690–697

  84. 84.

    . Statistical Genetics ‘98: Bayesian Linkage Analysis, or: How I Learned to Stop Worrying and Love the Posterior Probability of Linkage Am J Hum Genet 1998 63: 947–954

  85. 85.

    , . Statistical evidence: a likelihood paradigm (book review) Am J Hum Genet 1998 63: 283–289

  86. 86.

    , , . The power to detect linkage in complex disease by means of simple LOD-score analyses Am J Hum Genet 1998 63: 870–879

  87. 87.

    . 1996 William Allan Award Address. Algorithms and inferences: The challenge of multifactorial diseases Am J Hum Genet 1997 60: 255–262

  88. 88.

    . Methods of linkage analysis—and the assumptions underlying them Am J Hum Genet 1998 63: 931–934

  89. 89.

    , , , . Functional correlates of nicotine administration: similarity with drugs of abuse J Mol Med 1998 76: 193–201

  90. 90.

    , , , , , et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia Mol Psychiatry 1999 4: 247–253

  91. 91.

    , . Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results Nature Genet 1995 11: 241–247

  92. 92.

    , , , , . Comprehensive human genetic maps: individual and sex-specific variation in recombination Am J Hum Genet 1998 63: 861–869

  93. 93.

    , , , , , et al. A genetic linkage map of the human genome Cell 1987 51: 319–337

  94. 94.

    , , , , , et al. A microsatellite genetic linkage map of human chromosome 18 Genomics 1993 15: 48–56

  95. 95.

    , , , , , et al. Susceptibility genes for nicotine dependence: a genome scan and followup in an independent sample suggest that chromosomes 2, 4, 10, 16, 17 and 18 merit further study Mol Psychiatry 1999 4: 129–144

  96. 96.

    , , . Programs for pedigree analysis: MENDEL, FISHER, and dGENE Genet Epidemiol 1988 5: 471–472

  97. 97.

    , , , . Parametric and nonparametric linkage analysis: a unified multipoint approach Am J Hum Genet 1996 58: 1347–1363

  98. 98.

    , , . Direct power comparisons between simple LOD scores and NPL scores for linkage analysis in complex diseases Am J Hum Genet 1999 65: 847–857

  99. 99.

    , , . Magnitude of type I error when single-locus linkage analysis is maximized over models: a simulation study Am J Hum Genet 1997 60: 217–227

  100. 100.

    , , , , , . The Roscommon family study: IV. Affective illness, anxiety disorders, and alcoholism in relatives Arch Gen Psychiatry 1993 50: 952–960

  101. 101.

    , , , , . Replication of linkage studies of complex traits: an examination of variation in location estimates Am J Hum Genet 1999 65: 876–884

  102. 102.

    , , , , . Detecting marker-QTL linkage and estimating QTL gene effect and map location using a saturated genetic map Genetics 1993 134: 943–951

  103. 103.

    , . Complete multipoint sib-pair analysis of qualitative and quantitative traits Am J Hum Genet 1995 57: 439–454

  104. 104.

    , . Problems in the definition, interpretation, and evaluation of genetic heterogeneity Am J Hum Genet 2001 68: 457–465

  105. 105.

    , , . The putative schizophrenia locus on chromosome 6p: a brief overview of the linkage studies Mol Psychiatry 1996 1: 89–92

  106. 106.

    , , , , , et al. Genetic mapping using haplotype, association and linkage methods suggests a locus for severe bipolar disorder (BPI) at 18q22–q23 Nature Genet 1996 12: 436–441

  107. 107.

    , , , , , et al. Evidence of a locus for schizophrenia and related disorders on the short arm of chromosome 5 in a large pedigree Am J Med Genet 1996 67: 162–171

  108. 108.

    , , , , , et al. Localization of a susceptibility locus for schizophrenia on chromosome 5 Nature 1998 336: 164–167

  109. 109.

    , , , , , . Exclusion of a schizophrenia susceptibility gene from the chromosome 5q11–q13 region: new data and a reanalysis of previous reports Am J Hum Genet 1990 47: 524–535

  110. 110.

    , , , , , et al. Genome-wide scan for schizophrenia in the Finnish population: evidence for a locus on chromosome 7q22 [Abstract] Mol Psychiatry 1999 4 (Suppl. 1): S3

  111. 111.

    , , , , , . Analysis of epistasis in linked regions in the Irish study of high-density schizophrenia families Am J Med Genet 2001 105: 266–270

  112. 112.

    , , , , . Multi-locus nonparametric linkage analysis of complex trait loci with neural networks Hum Hered 1998 48: 275–284

  113. 113.

    . CAT scans, PET scans, and genomic scans Genet Epidemiol 1998 15: 1–18

  114. 114.

    , . Neurobiology of schizophrenia Curr Opin Neurobiol 1997 7: 701–707

  115. 115.

    , , , , . Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex Neuron 2000 28: 53–67

Download references

Author information

Affiliations

  1. Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA

    • R E Straub
    • , C J MacLean
    • , Y Ma
    • , B T Webb
    • , B Wormley
    • , B Kadambi
    •  & K S Kendler
  2. Department of Human Genetics, Virginia Commonwealth University, Richmond, VA, USA

    • K S Kendler
  3. Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA

    • R E Straub
    • , C J MacLean
    • , Y Ma
    • , B T Webb
    • , B Wormley
    • , B Kadambi
    •  & K S Kendler
  4. The Department of Psychiatry, The Queens University, Belfast, Northern Ireland

    • F A O'Neill
  5. The Health Research Board, Dublin, Ireland

    • D Walsh
  6. Genaissance Pharmaceuticals, Inc, New Haven, CT, USA

    • C Harris-Kerr
  7. Laboratory of Biochemistry, NIH/NCI, Bethesda, MD, USA

    • M V Myakishev
  8. Commonwealth Biotechnologies, Inc, Richmond, VA, USA

    • H Sadek

Authors

  1. Search for R E Straub in:

  2. Search for C J MacLean in:

  3. Search for Y Ma in:

  4. Search for B T Webb in:

  5. Search for M V Myakishev in:

  6. Search for C Harris-Kerr in:

  7. Search for B Wormley in:

  8. Search for H Sadek in:

  9. Search for B Kadambi in:

  10. Search for F A O'Neill in:

  11. Search for D Walsh in:

  12. Search for K S Kendler in:

Corresponding author

Correspondence to R E Straub.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/sj.mp.4001051